Forgot your password?
The European Commission (EC) has approved Regeneron and Sanofi’s Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU), marking the first approval of a targeted treatment for the condition in more than a decade.
Newly released three-year data from UCB’s Be Heard trials of Bimzelx (bimekizumab) have shown long-term efficacy in treating hidradenitis suppurativa (HS).
ImmunoSkin, Almirall’s annual scientific meeting for the discussion of chronic inflammatory skin conditions, has been held for the fourth time, gathering international experts to consider advances in science and treatment.
Positive top-line results from two phase 3 studies of upadacitinib (RINVOQ) in adult and adolescent patients with non-segmental vitiligo (NSV) have been announced by AbbVie.
Newly released results from LEO Pharma’s phase 3b ADHAND trial have supported the efficacy and safety of Adbry (tralokinumab) for adults with atopic dermatitis (AD) involving the hands.
Meta-analysis of recent drug trials for Galderma’s Nemluvio (nemolizumab) have evaluated its efficacy and safety in the treatment of prurigo nodularis (PN), highlighting strong therapeutic potential.
A new pre-filled syringe version of Shingrix, GSK’s vaccine for shingles, has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
New findings from Johnson & Johnson’s global ENCOMPASS study have revealed significant unmet needs, as well as patient and provider treatment preferences, in psoriasis.
The rare skin conditions affect approximately 500,000 people globally
Around 30% of psoriasis patients are affected by psoriatic arthritis